Tachycardia-induced change of atrial refractory period in humans: Rate dependency and effects of antiarrhythmic drugs

Circulation

Volumn 97, Issue 23, 1998, Pages 2331-2337

  Yu, Wen Chung ^b   Chen, Shih Ann ^a,b   Lee, Shih Huang ^a   Tai, Ching Tai ^b   Feng, An Ning ^b   Kuo, Benjamin Ing Tiau ^b   Ding, Yu An ^b   Chang, Mau Song ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Antiarrhythmia agents; Atrium; Electrophysiology; Fibrillation

Indexed keywords

AMIODARONE; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; SOTALOL; VERAPAMIL;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HEART RHYTHM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY PERIOD; TACHYCARDIA;

EID: 0032537611     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.23.2331     Document Type: Article

References (31)

1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation. N Engl J Med. 1982;306:1018-1022.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 1987;147:1561-1564.
3. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham study. JAMA. 1985;254:3449-3453.
4. Davidson E, Rotenberg Z, Weinberger I, Fuchs J, Agmon J. Diagnosis and characteristics of lone atrial fibrillation. Chest. 1989;95:1048-1050.
5. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR, Ilstrup DM. Frye RL. The nature history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med. 1987;317:669-674.
6. Godtfredsen J. Atrial Fibrillation: Etiology, Course and Prognosis: A Follow-up Study of 1212 Cases. Copenhagen, Denmark: Munksgaard University; 1975, Thesis.
7. Suttorp MJ, Kingma HJ, Jessurun ER, Lie-A-Huen L, Van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol. 1990;16:1722-1727.
8. Waris E, Kreus K, Salokannel J. Factors influencing persistence of sinus rhythm after DC shock treatment of atrial fibrillation. Acta Med Scand. 1971;189:161-166.
9. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA, Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92:1954-1968.
10. Daoud EG, Bogum F, Goyal R, Harvey M, Man KC, Strickberger SA, Morady F. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation. 1996;94:1600-1606.
11. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation: time course and mechanisms. Circulation. 1996;94:2968-2974.
12. Fenster PE, Comess KA, Marsh R, Katzenberg C, Hager WD. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J. 1983;106:501-504.
13. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Prichett EL. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring: Flecainide Supraventricular Tachycardia Study Group. Circulation. 1989;80:1557-1570.
14. Pritchett ELC, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: a randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med. 1991;114:539-544.
15. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1993;71:558-563.
16. Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, Brady PM, Kay HR. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol. 1985;6:1402-1407.
17. David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added β-adrenergic blocking agent. Am J Cardiol. 1979;44:1378-1382.
18. Waxman HL, Myerburg RJ, Appel R, Sung RJ. Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study. Ann Intern Med. 1981;94:1-6.
19. Cox JL, Canavan TE, Schuessler RB, Cain ME, Lindsay BD, Stone C, Smith PK, Corr PB, Boineau JB. The surgical treatment of atrial fibrillation, II: intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg. 1991;101:406-426.
20. Wang Z, Page PL, Nattel S. Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation. Circ Res. 1992;71:271-278.
21. Konings KTS, Kirchhof CJHJ, Smeets JRLM, Wellens HJJ, Penn OC, Allessie MA. High density mapping of electrically induced atrial fibrillation in man. Circulation. 1994;89:1665-1680.
22. Smeets JLRM, Allessie MA, Lammers WJEP, Bonke FIM, Hollen SJ. The wavelength of the cardiac impulse and reentrant arrhythmias in isolated rabbit atrium: the role of heart rate, autonomic transmitters, temperature, and potassium. Circ Res. 1986;58:96-108.
23. Rensma PL, Allessie MA, Lammers WJEP, Bonke FIM, Schallij MJ, Length of excitation wave and susceptibility to reentrant atrial arrhythmias in conscious dogs. Circ Res. 1988;62:395-410.
24. Morillo CA, Klein GJ, Jones DL, Guirauddon CM. Chronic rapid atrial pacing: structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation. 1995;91:1588-1595.
25. Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs: electrophysiological remodeling. Circulation. 1996;94:2953-2960.
26. Tieleman RG, Langen CDJD, Van Gelder IC, Kam PJD, Grandjean J, Bel KJ, Wijffels MCEF, Allessie MA, Crijns HJGM. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation. 1997;95:1945-1953.
27. Fuchs T, Podrid PJ. Pharmacologic therapy for reversion of atrial fibrillation and maintenance of sinus rhythm. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation: Mechanisms and Management. New York, NY: Raven Press; 1992:253-254.
28. Koretsune Y, Marban E. Cell calcium in the pathophysiology of ventricular fibrillation and in the pathogenesis of postarrhythmic contractile dysfunction. Circulation. 1989;80:369-379.
29. Leistad E, Aksnes G, Verburg E, Christensen G. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. Circulation. 1996;93:1747-1754.
30. Daoud EG, Knight BP, Weiss R, Bahu M, Paladino W, Goyal R, Man C, Strickberger SA, Morady F. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation. 1997;5:1542-1550.
31. Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action: mechanism of potassium channel blocker and its role in suppressing and aggravating cardiac arrhythmias. Circulation. 1990;82:2235-2242.